Bielčiková Zuzana, Jakabová Anna, Pinkas Michael, Zemanová Milada, Kološtová Katarína, Bobek Vladimír
Department of Oncology, First Faculty of Medicine, Charles University and General University Hospital in Prague, U Nemocnice 499/212808 Prague, Czech Republic.
Department of Laboratory Genetics, University Hospital Kralovske Vinohrady, Srobarova 5010034 Prague, Czech Republic.
Am J Transl Res. 2017 Jun 15;9(6):2807-2823. eCollection 2017.
Circulating tumor cells (CTC) present in peripheral blood are assigned precursors of advanced tumor disease. Simplicity of blood withdrawal procedure adds practically an unlimited possibility of the CTC-monitoring and the advantages of the repeated biopsies over time. CTC got prognostic, predictive and diagnostic status with the technologic advance. Although the clinical utility of CTC has reached the high evidence, the significance of CTC testing was presented in the treatment strategy mostly with palliative intention. We report on the experiences with the CTC-testing in the CLIA-like laboratory working with the size-based CTC separation and culture. The data is presented in the form of case reports in patients with breast (BC), colorectal (CRC), prostate (PC) and lung cancer (NSCLC) to support the clinical utility of CTC during the neoadjuvant, adjuvant and palliative treatment. The presented findings support the evidence for liquid biopsy clinical implementation and enhance the ability of malignant disease monitoring and the treatment efficacy prediction.
外周血中存在的循环肿瘤细胞（CTC）被视为晚期肿瘤疾病的前体。采血过程简单，这实际上为CTC监测提供了无限可能，且随着时间推移具有重复活检的优势。随着技术进步，CTC获得了预后、预测和诊断地位。尽管CTC的临床应用已获得高度证据支持，但CTC检测在治疗策略中的意义主要体现在姑息治疗意图方面。我们报告了在类似CLIA实验室中进行CTC检测的经验，该实验室采用基于大小的CTC分离和培养方法。数据以乳腺癌（BC）、结直肠癌（CRC）、前列腺癌（PC）和肺癌（NSCLC）患者的病例报告形式呈现，以支持CTC在新辅助、辅助和姑息治疗期间的临床应用。所呈现的研究结果支持液体活检临床应用的证据，并增强了对恶性疾病的监测能力和治疗疗效预测能力。
